A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Parallel Study to Investigate the Pharmacokinetics, Pharmacodynamic Effects, Safety and Tolerability of Repeated Dosing of RG7625 in Volunteers With Celiac Disease
Phase of Trial: Phase I
Latest Information Update: 16 Sep 2016
At a glance
- Drugs RG 7625 (Primary)
- Indications Coeliac disease
- Focus Therapeutic Use
- Sponsors Roche
- 01 Sep 2016 Status changed from recruiting to completed.
- 01 Aug 2016 Planned End Date changed from 1 Jul 2016 to 1 Sep 2016.
- 01 Aug 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Sep 2016.